Overview

Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer

Status:
Not yet recruiting

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study. In the current study, the efficacy and safety of anlotinib hydrochloride combined with nivolumab as second-line or salvage chemotherapy will be evaluated in Chinese patients with advanced gastric adenocarcinoma and esophageal squamous cell carcinoma. 48 patients could provide adequate precision rather than controlling type I&II error.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

Nivolumab